var data={"title":"Vitamin B6 (pyridoxine): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin B6 (pyridoxine): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6879?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-b6-pyridoxine-drug-information\" class=\"drug drug_general\">see &quot;Vitamin B6 (pyridoxine): Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-b6-pyridoxine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin B6 (pyridoxine): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216001\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neuro-K-250 T.D. [OTC];</li>\n      <li>Neuro-K-250 Vitamin B6 [OTC];</li>\n      <li>Neuro-K-50 [OTC];</li>\n      <li>Neuro-K-500 [OTC];</li>\n      <li>Pyri 500 [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061707\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cycloserine Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hydrazine Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Mushroom Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Drug-induced Neuritis, Treatment Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Water Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444894\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Adequate intake (AI):</b> Oral: 0.1 mg/day (0.01 mg/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pyridoxine-dependent seizures:</b> Oral, IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial: IV preferred: 50 to 100 mg (Rajesh, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance: Oral preferred: Usual: 50 to 100 mg/day; range: 10 to 200 mg (Rajesh, 2003); an observational study in UK described a usual dose of 30 mg/kg/day (Baxter, 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061701\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-b6-pyridoxine-drug-information\" class=\"drug drug_general\">see &quot;Vitamin B6 (pyridoxine): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Adequate intake (AI):</b> Oral: Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to &lt;6 months: 0.1 mg (0.01 mg/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">6 to 12 months: 0.3 mg (0.03 mg/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Recommended daily allowance (RDA):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to 3 years: 0.5 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">4 to 8 years: 0.6 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">9 to 13 years: 1 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">14 to 18 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Male: 1.3 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Female: 1.2 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Dietary deficiency; treatment:</b> Oral, IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 5 to 25 mg/day for 3 weeks, then 2.5 to 5 mg/day in multivitamin product</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: 10 to 20 mg/day for 3 weeks, then 2 to 5 mg/day (usual dosage  found in multivitamin products)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pyridoxine-dependent seizures, treatment:</b> Oral, IM, IV: Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial: IV preferred: 50 to 100 mg (Rajesh, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: Oral preferred: Usual: 50 to 100 mg/day; range: 10 to 200 mg (Rajesh, 2003); an observational study in UK described a usual dose of 30 mg/kg/day (Baxter, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Drug-induced deficiency/toxicity (cycloserine, isoniazid, penicillamine); chronic use:</b> Oral, IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Isoniazid/Cycloserine: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Prevention: <b>Note:</b> Recommended for patients at risk: Exclusively breast-fed infants, meat- and milk-deficient diet, nutritional deficiency, pregnant adolescents (<i>Red Book</i>, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Non-HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Infants and Children: 1 mg/kg/day; usual range: 10 to 50 mg/day (<i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Adolescents: 30 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Infants and Children: 1 to 2 mg/kg once daily; maximum daily dose: 50 mg/day (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Adolescents:  25  mg/day (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Treatment: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Infants and Children: Optimal dose not established, higher doses than prophylaxis are necessary for treatment of neuritis (ataxia), some clinicians have suggested the following: 100 mg/day; higher doses (ie, 200mg/day) may be necessary to alleviate signs/symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Adolescents: Initial: 100 mg/day for 3 weeks followed by 30 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Penicillamine (in Wilson Disease patients):</i> Limited data available: Children and Adolescents: 25 to 50 mg/day (Roberts, 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute isoniazid ingestion: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\"> <i>Treatment of isoniazid-induced seizures and/or coma</i>: IV: Children and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Acute ingestion of known amount: Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 70 mg/kg up to 5 g); administer at a rate of 0.5 to 1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland, 2006; Morrow, 2006). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Acute ingestion of unknown amount: Initial: 70 mg/kg (maximum dose: 5 g); administer at a rate of 0.5 to 1 g/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006; Santucci, 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Prevention of isoniazid-induced seizures and/or coma:</i> IV: Children: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Boyer, 2006). Dosing recommendations are the same as for the treatment of symptomatic patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute intoxication:</b> Children and Adolescents: Mushroom ingestion (genus <i>Gyromitra</i>): IV: 25 mg/kg/dose; repeat as necessary to a maximum total dose of 15 to 20 g (Lheureaux, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Recommended daily allowance:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">19 to 50 years: 1.3 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;50 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Female: 1.5 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Male: 1.7 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pregnancy:  1.9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Lactation:  2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Dietary deficiency:</b> Oral, IM, IV: Adults: 10 to 20 mg/day for 3 weeks, then 2-5 mg/day (usual dosage found in multivitamin products). Doses up to 600 mg/day may be needed with pyridoxine dependency syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Drug-induced neuritis</b> (eg, isoniazid): Oral, IM, IV: Prophylaxis: HIV-exposed/-positive: 25 mg/day; 50 mg/day if pregnant (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Treatment of isoniazid-induced seizures and/or coma following acute ingestion:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Acute ingestion of known amount: Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 5000 mg); administer at a rate of 500 to 1000 mg/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland, 2006; Morrow, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Acute ingestion of unknown amount: Initial: 5000 mg; administer at a rate of 500 to 1000 mg/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prevention of isoniazid-induced seizures and/or coma following acute ingestion:</b> IV: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Boyer, 2006). Dosing recommendations are the same as for the treatment of symptomatic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute intoxication:</b> Mushroom ingestion (genus <i>Gyromitra</i>): IV: 25 mg/kg/dose; repeat as necessary to a maximum total dose of 15 to 20 g (Lheureaux, 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215977\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-250 T.D.: 250 mg [corn free, rye free, starch free, sugar free, wheat free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-50: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-500: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-250 Vitamin B6: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pyri 500: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215962\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061712\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer without regard to meals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: May be administered IM or  slow IV; seizures have been precipitated following large IV doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isoniazid toxicity: Initial doses should be administered at a rate of 500-1000 mg/minute. If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via nasogastric (NG) tube (Boyer, 2006) or an extemporaneous compounded solution may be used. Oral administration is not recommended for acutely poisoned patients with seizure activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215996\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store at room temperature. Avoid excessive heat or moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061711\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and treatment of vitamin B<sub>6</sub> deficiency; treatment of drug-induced deficiency (eg, isoniazid or oral contraceptives); treatment of inborn errors of metabolism (eg, B<sub>6</sub>-dependent seizures or anemia); injection may be used when oral route not feasible (All indications: FDA approved in adults); has also been used for the treatment of  pyridoxine-dependent seizures and treatment of acute intoxication of isoniazid, cycloserine, hydrazine, and mushroom (genus <i>Gyromitra</i>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216049\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pyridoxine may be confused with paroxetine, pralidoxime, Pyridium</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxal [Brazil] may be confused with Doxil brand name for DOXOrubicin [U.S.]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxal: Brand name for pyridoxine/thiamine combination [Brazil], but also the brand name for doxepin [Finland]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216046\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, drowsiness, headache, neuropathy, paresthesia, seizure (following very large IV doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, folate deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215986\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyridoxine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215966\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Severe, permanent peripheral neuropathies have been reported; neurotoxicity is more common with long-term administration of large doses (&gt;2 g/day) (Albin 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence/withdrawal: Doses &gt;200 mg/day may cause dependence and withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pharmacy supply of emergency antidotes: Guidelines suggest that at least 8 to 24 g be stocked. This is enough to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period. In areas where tuberculosis is common and isoniazid toxicity is more likely, hospitals should consider stocking 24 g. This is enough to treat 1 patient for 24 hours (Dart 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299968\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215971\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12753&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day) <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215974\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215989\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Water soluble vitamins cross the placenta. Maternal pyridoxine plasma concentrations may decrease as pregnancy progresses and requirements may be increased in pregnant women (IOM 1998). Pyridoxine is used to treat nausea and vomiting of pregnancy (Neibyl 2010). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061706\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">When administering large IV doses, monitor respiratory rate, heart rate, and blood pressure</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For treatment of isoniazid, hydrazine, or gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061710\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">30-80 ng/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215965\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Precursor to pyridoxal, which functions in the metabolism of proteins, carbohydrates, and fats; pyridoxal also aids in the release of liver and muscle-stored glycogen and in the synthesis of GABA (within the central nervous system) and heme</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215985\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed (IOM 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to pyridoxal phosphate and pyridoxamine phosphate (active forms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biologic: 15 to 20 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215984\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral solution may be made using pyridoxine injection. Withdraw 100 mg (1 mL of a 100 mg/mL injection) from a vial with a needle and syringe; add to 99 mL simple syrup in an amber bottle. Label &quot;refrigerate&quot;. Stable for 30 days refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neuro-K-250 T.D. Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pyridoxine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $18.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyridoxine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1000): $11.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $8.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $5.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215991\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AFI-B6 (NO);</li>\n      <li>B(6)-Vicotrat (DE);</li>\n      <li>Becilan (FR);</li>\n      <li>Bedoxine (BE, LU);</li>\n      <li>Bedoyecta (MX);</li>\n      <li>Beesix (ZA);</li>\n      <li>Benadon (AR, AT, CH, ES, GB, IE, IT, PT, SE);</li>\n      <li>Bexivit (GR);</li>\n      <li>Biprin (CO);</li>\n      <li>Bivit (IT);</li>\n      <li>Burgerstein Vitamin B6 (CH);</li>\n      <li>Comploment Continus (AE, BH, CH, CY, EG, IE, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dermo 6 (FR);</li>\n      <li>Dodemina (MX);</li>\n      <li>Dolvifen (MX);</li>\n      <li>Farmobion B6 (IT);</li>\n      <li>Glutarase (IT);</li>\n      <li>Heksavit (FI);</li>\n      <li>Hexobion 100 (DE);</li>\n      <li>Hysix (JP);</li>\n      <li>Incremin con hierro (MX);</li>\n      <li>M. V. I. 12 (MX);</li>\n      <li>Memosprint (IT);</li>\n      <li>Natele (MX);</li>\n      <li>Nuro-B (MX);</li>\n      <li>Pharmaton (MX);</li>\n      <li>Pidopidon (JP);</li>\n      <li>Piridoxina Austral (AR);</li>\n      <li>Plivit B6 (HR);</li>\n      <li>Poly-B con Vitamina C (MX);</li>\n      <li>Pyricontin Continus (IN);</li>\n      <li>Pyridoxin Recip[Tab.] (SE);</li>\n      <li>Pyridoxin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Pyridoxine Aguettant (FR);</li>\n      <li>Pyridoxine Renaudin (FR);</li>\n      <li>Pyridoxine-Labaz (LU);</li>\n      <li>Pyrivitol (AT);</li>\n      <li>Pyroxin (AU);</li>\n      <li>Reisevit (AT);</li>\n      <li>Sechvitan (JP);</li>\n      <li>Tanvimil B6 (AR);</li>\n      <li>Trineurovita (MX);</li>\n      <li>Vit. B6 Agepha (AT);</li>\n      <li>Vita-B6 (FI);</li>\n      <li>Vitamin B6 (HU);</li>\n      <li>Vitamin B6 Streuli (CH);</li>\n      <li>Vitamine B6 Richard (FR);</li>\n      <li>Vitaminum B6 (PL);</li>\n      <li>Xanturenasi (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter P. Epidemiology of pyridoxine dependent and pyridoxiine responsive seizures in the UK. <i>Arch Dis Child</i>. 1999; 81:431-433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/10519720/pubmed\" target=\"_blank\" id=\"10519720\">10519720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW, &ldquo;Antituberculous Medications,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman, RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 861-71.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Borron SW, Caravati EM, et al,&ldquo;Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care,&rdquo; <i>Ann Emerg Med</i>, 2009, 54(3):386-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/19406507/pubmed\" target=\"_blank\" id=\"19406507\">19406507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health and Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diaz JH, &ldquo;Syndromic Diagnosis and Management of Confirmed Mushroom Poisonings,&rdquo; <i>Crit Care Med</i>, 2005, 33(2):427-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/15699849/pubmed\" target=\"_blank\" id=\"15699849\">15699849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foukas MD, &quot;An Antilactogenic Effect of Pyridoxine,&quot; <i>J Obstet Gynaecol BrCommonw</i>, 1973, 80(8):718-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/4579974/pubmed\" target=\"_blank\" id=\"4579974\">4579974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA, &ldquo;Antidotes in Depth: Pyridoxine,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 872-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine). Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B<sub>6</sub>, folate, vitamin B<sub>12</sub>, pantothenic acid, biotin, and choline.Washington, DC:The National Academies Press, 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lheureaux P, Penaol A, and Gri M. Pyridoxine in clinical toxicology: a review. <i>Eur J of Emerg Med</i>. 2005;12(2):78-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/15756083/pubmed\" target=\"_blank\" id=\"15756083\">15756083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morrow LE, Wear RE, Schuller D, et al, &quot;Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies,&quot; <i>Pharmacotherapy</i>, 2006, 26(10):1529-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/16999664/pubmed\" target=\"_blank\" id=\"16999664\">16999664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagappan R and Riddell T, &ldquo;Pyridoxine Therapy in a Patient With Severe Hydrazine Sulfate Toxicity,&rdquo; <i>Crit Care Med</i>, 2000, 28(6):2116-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/10890675/pubmed\" target=\"_blank\" id=\"10890675\">10890675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niebyl JR, &quot;Clinical Practice. Nausea and Vomiting in Pregnancy,&quot; <i>N Engl J Med</i>, 2010, 363(16):1544-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/20942670/pubmed\" target=\"_blank\" id=\"20942670\">20942670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajesh R and Girija AS, &quot;Pyridoxine-Dependent Seizures: A Review,&quot; <i>Indian Pediatr</i>, 2003, 40(7):633-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/12881619/pubmed\" target=\"_blank\" id=\"12881619\">12881619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts EA, Schilsky ML, and American Association for Study of Liver Diseases (AASLD).  Diagnosis and treatment of Wilson disease: an update. <i>Hepatology</i>. 2008;47(6):2089-2111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/abstract-text/18506894/pubmed\" target=\"_blank\" id=\"18506894\">18506894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santucci KA, Shah BR, and Linakis JG, &quot;Acute Isoniazid Exposures and Antidote Availability,&quot; <i>Pediatric Emergency Care</i>, 1999, 15(2):99-101.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12753 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216001\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061707\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444894\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061701\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215977\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F215962\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061712\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F215996\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061711\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216049\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216046\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215986\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215966\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299968\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215971\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215974\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F215989\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061706\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1061710\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215965\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F215985\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F215984\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215991\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12753|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-b6-pyridoxine-drug-information\" class=\"drug drug_general\">Vitamin B6 (pyridoxine): Drug information</a></li><li><a href=\"topic.htm?path=vitamin-b6-pyridoxine-patient-drug-information\" class=\"drug drug_patient\">Vitamin B6 (pyridoxine): Patient drug information</a></li></ul></div></div>","javascript":null}